| Literature DB >> 27213130 |
Sandro Gentile1, Giuseppina Guarino1, Annalisa Giancaterini2, Piero Guida3, Felice Strollo4.
Abstract
BACKGROUND: Lipohypertrophy (LH) is a major complication of subcutaneous insulin treatment brought about by multiple overlapping injections and/or needle reuse. It is responsible for unacceptable glucose oscillations due to a high rate of hypoglycaemic episodes and rebound glucose spikes. Skin ultrasound scans (USS), the gold standard for its detection, is too expensive for screening purposes. AIMS: To define a structured method allowing health professionals (HPs) to identify LH lesions as inexpensively and correctly as possible.Entities:
Keywords: Diabetes; Injection; Insulin; Lesions; Lipohypertrophy
Year: 2016 PMID: 27213130 PMCID: PMC4859222 DOI: 10.1186/s40064-016-1978-y
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Lipohyperthophy prevalence variability among different case studies
| Publication year | Prevalence (%) | Author | Diabetes type 1 or 2 | |
|---|---|---|---|---|
| Seyoum | 1996 | 31.0 | 9 | 1 + 2 |
| Hauner | 1996 | 28.7 | 10 | 1 |
| Partanen | 2000 | 34.5 | 11 | 1 |
| Raile | 2001 | 27.1 | 12 | 1 |
| Kordonouri | 2002 | 48.0 | 13 | 1 |
| Vardar | 2007 | 48.8 | 14 | 1 + 2 |
| Hajheydari | 2011 | 14.5 | 15 | 1 + 2 |
| Teft | 2002 | 57.0 | 16 | 1 + 2 |
| Blanco | 2013 | 64.0 | 17 | 1 + 2 |
| Grassi | 2014 | 49.0 | 18 | 1 + 2 |
| McNally | 1988 | 28.0 | 19 | 2 |
| Hauner | 1996 | 3.6 | 10 | 2 |
Patient features by lipohypertrophy (LH) site, shape and size
| Overall | Site | Shape | Diameter | |||||
|---|---|---|---|---|---|---|---|---|
| Abdomen | Arm | Thigh | Flat | Protruding | ≤4 cm | >4 cm | ||
| n = 40 | n = 16 | n = 14 | n = 10 | n = 22 | n = 18 | n = 20 | n = 20 | |
| Female gender | 60 % | 12 (75 %) | 8 (57 %) | 4 (40 %) | 16 (72.7 %) | 8 (44.4 %) | 10 (50 %) | 14 (70 %) |
| BMI (kg/m2) | 29.1 ± 2.4 | 28.8 ± 3.2 | 29.7 ± 2.3 | 28.5 ± 1.2 | 29 ± 2.1 | 29.1 ± 2.9 | 28.8 ± 1.8 | 29.4 ± 3 |
| LH site | ||||||||
| Abdomen | 16 (40 %) | 16 (100 %) | 0 (0 %) | 0 (0 %) |
|
|
|
|
| Arm | 14 (35 %) | 0 (0 %) | 14 (100 %) | 0 (0 %) |
|
|
|
|
| Thigh | 19 (25 %) | 0 (0 %) | 0 (0 %) | 10 (100 %) |
|
|
|
|
| LH shape | ||||||||
| Flat | 22 (55 %) |
|
|
| 22 (100 %) | 0 (0 %) | 16 (80 %) | 6 (30 %) |
| Protruding | 18 (45 %) |
|
|
| 0 (0 %) | 18 (100 %) | 4 (20 %) | 14 (70 %) |
| LH size | ||||||||
| Diameter (cm) | 4.8 ± 1.5 |
|
|
|
|
| 3.6 ± 0.5 | 6.1 ± 1.1 |
| Diameter ≤ 4 cm | 20 (50 %) |
|
|
| 16 (72.7 %) | 4 (22.2 %) | 20 (100 %) | 0 (0 %) |
| Diameter > 4 cm | 20 (50 %) |
|
|
| 6 (27.3 %) | 14 (77.8 %) | 0 (0 %) | 20 (100 %) |
Mean ± standard deviation or rate (percentage). Italics characters are used for statistically significant comparisons (p < 0.05)
Fig. 1Lipohypertrophy features. Moderate swelling of the abdominal wall below the umbilicus, the site most often chosen by the patient for insulin injections; his right hand pinches a thick fold in the presence of a large lipohypertrophy skin plate (a); while only a thin fold results from the left hand squeezing the area systematically ignored for insulin shots (b)
Fig. 2Lipohyertrophy identification technique. The figure shows how to identify a LH lesion after a thorough inspection of the area by performing repeated vertical and horizontal finger tip movements over and around it (a–c), pinching it (d–f) and marking it (g) and how to finally measure it (h)
Lipohypertrophy identification rate for Well Trained (WT) and Non-Trained (NT) health professionals by site, shape and size
| Overall | Site | Shape | Diameter | |||||
|---|---|---|---|---|---|---|---|---|
| Abdomen | Arm | Thigh | Flat | Protruding | ≤4 cm | >4 cm | ||
| n = 40 | n = 16 | n = 14 | n = 10 | n = 22 | n = 18 | n = 20 | n = 20 | |
| WT | ||||||||
| 1 | 40 (100 %) | 16 (100 %) | 14 (100 %) | 10 (100 %) | 22 (100 %) | 18 (100 %) | 20 (100 %) | 20 (100 %) |
| 2 | 36 (90 %) | 16 (100 %) | 10 (71 %) | 10 (100 %) | 18 (82 %) | 18 (100 %) | 18 (90 %) | 18 (90 %) |
| 3 | 38 (95 %) | 16 (100 %) | 12 (86 %) | 10 (100 %) | 20 (91 %) | 18 (100 %) | 18 (90 %) | 20 (100 %) |
| 4 | 40 (100 %) | 16 (100 %) | 14 (100 %) | 10 (100 %) | 22 (100 %) | 18 (100 %) | 20 (100 %) | 20 (100 %) |
| NT | ||||||||
| 1 | 28 (70 %) | 14 (88 %) | 4 (29 %) | 10 (100 %) | 10 (46 %) | 18 (100 %) | 10 (50 %) | 18 (90 %) |
| 2 | 24 (60 %) | 14 (88 %) | 4 (29 %) | 6 (60 %) | 10 (46 %) | 14 (78 %) | 8 (40 %) | 16 (80 %) |
| 3 | 32 (80 %) | 12 (75 %) | 10 (71 %) | 10 (100 %) | 18 (82 %) | 14 (78 %) | 16 (80 %) | 16 (80 %) |
| 4 | 22 (55 %) | 14 (88 %) | 4 (29 %) | 4 (40 %) | 8 (36 %) | 14 (78 %) | 6 (30 %) | 16 (80 %) |
Fig. 3Lipohypertrophy identification results obtained by trained and non-trained health professionals as referred to the shape, site and size of skin lesions (% stays for identification rate)
Univariate and multivariate predictors of missed lipohypertrophy (LH) identification by well trained (WT) and non-trained (NT) health professionals (HPs)
| Univariate | p | Multivariate | p | |
|---|---|---|---|---|
| NT | ||||
| Female gender | 1.91 (0.32–11.50) | 0.480 | ||
| BMI (Kg/m2) | 1.29 (0.89–1.87) | 0.172 | – | |
| LH site | ||||
| Abdomen | 1.00 | – | ||
| Arm |
|
|
|
|
| Thigh | 1.90 (0.34–10.67) | 0.467 | – | 0.999 |
| LH shape | ||||
| Protruding | 1.00 | – | ||
| Flat |
|
| 0.84 (0.14–5.20) | 0.855 |
| LH size | ||||
| Diameter ≤4 cm |
|
| 3.78 (0.92–15.58) | 0.066 |
| Overall | ||||
| NT versus WT |
|
|
|
|
| Female gender | 1.88 (0.31–11.44) | 0.492 | – | |
| BMI (Kg/m2) | 1.31 (0.91–1.89) | 0.150 | – | |
| LH site | ||||
| Abdomen | 1.00 | – | ||
| Arm |
|
|
|
|
| Thigh | 1.86 (0.34–10.18) | 0.475 | – | |
| LH shape | ||||
| Protruding | 1.00 | – | ||
| Flat |
|
| 0.92 (0.14–5.84) | 0.930 |
| LH size | ||||
| Diameter ≤4 cm |
|
| 3.17 (0.78–12.81) | 0.106 |
Univariate analysis in the overall group was performed after adjusting for HPs’ experience (NT o WT)